Liver/Biliary Disorders News

Declines in serum hepatitis B virus RNA at the first and second year of treatment with nucleos(t)ide analogues correlated with risk for hepatocellular carcinoma and may serve as independent predictors of cancer development.

An intermittent calorie restriction diet was “safe and more effective” in reducing hepatic steatosis at 12 weeks vs. a standard of care diet in metabolic dysfunction-associated steatotic liver disease, particularly among those with obesity.

Vitamin E improved serum markers of liver inflammation and histology in patients with metabolic dysfunction-associated steatotic liver disease, according to results from a systematic review and meta-analysis.

Both stretching and meditation reduced cramp severity and improved quality of life among patients with cirrhosis and may be considered as nonpharmacologic interventions when treating nocturnal muscle cramps, according to researchers.

Over recent years, there has been increased interest and attention to hepatitis delta virus, as we are beginning to understand that this is a real problem that at the moment is under-addressed and under-identified.

Despite being the smallest virus capable of causing human disease, it is estimated that up to 80% of patients with hepatitis delta virus will progress to liver cirrhosis and more than 50% will die of liver disease within 10 years of diagnosis.

Neoadjuvant immunotherapy may allow more people with hepatocellular carcinoma to undergo surgical resection, according to retrospective study results.

A model using both clinical and imaging data predicted the absence of high-risk varices in patients with unresectable hepatocellular carcinoma and may help avoid unnecessary upper endoscopy in low-risk patients, research showed.

Gilead’s Livdelzi, a selective peroxisome proliferator-activated receptor delta agonist, has received accelerated FDA approval for the treatment of primary biliary cholangitis, according to a company release.

A hepatitis C elimination program in Georgia reduced the estimated annual incidence of new infections by 61% since its launch in April 2015, which may accelerate efforts to reach the global 2030 elimination goal.